About

ClearSight Therapeutics, founded in 2023, is an ocular biotechnology company transforming a stagnant eye care market with a permanently cationic biopolymer derived from crustacean shells that forms a bioadhesive barrier and delivers broad-spectrum antimicrobial protection without driving resistance.
Addressing a $5+ billion U.S. market where nearly one in three Americans suffers from dry eye, contact lens irritation, or pink eye—and where existing OTC products merely lubricate rather than protect—ClearSight is launching three differentiated over-the-counter products: Artificial Tears+, Contact Lens Rewetting Drops, and the first and only OTC antimicrobial pink eye drop.
Backed by $84 million in five-year commercial commitments, the company begins revenue in 2027, targets breakeven in 2028, and projects more than $50 million in sales by 2032, combining deep chemistry with near-term retail deployment to bring next-generation biology to the shelf.